Foghorn Therapeutics Inc. Common Stock (FHTX)
Stock · NASDAQ · Health Care
$1.86as of 10/16/2026
Price chart
Active signals
FHTX Signal Track Record
How signals performed across all stocks →What FHTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +4.7% | 54% | October 1, 2026 |
| Bollinger Band Breakout | 25 | -7.6% | 32% | August 7, 2026 |
| Bollinger Band Breakdown | 22 | -3.4% | 45% | October 1, 2026 |
| 200-Day Moving Average TouchActive now | 21 | +2.1% | 52% | July 24, 2026 |
| Any 20-session window (baseline) | -0.4% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About FHTX
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 106
- Website
- foghorntx.com/
Fundamentals
- 1-day range
- $1.82$1.91
- Market cap
- $327.04M
- P/E (trailing)
- —
- P/E (forward)
- -1.84
- EPS (trailing)
- $-0.98
- Dividend yield
- —
- Beta
- 3.13
- Avg. volume
- 662.3K
How Foghorn Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2024 annual results
Source: 10-K filed Mar 6, 2025 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Foghorn Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- FHTXFoghorn Therapeutics Inc. Common Stock$1.85▼ 2.12%Market cap $327.04MP/E —$1.79$7.61
- GALTGalectin Therapeutics Inc. Common Stock$3.62▼ 2.43%Market cap $324.74MP/E —$2.03$7.13
- CATXPerspective Therapeutics Inc. Common Stock$2.17▼ 7.26%Market cap $338.72MP/E —$1.96$6.16
- ORGOOrganogenesis Holdings Inc. Class A Common Stock$1▼ 9.91%Market cap $310.11MP/E 84.95$1.13$7.08
- VNDAVanda Pharmaceuticals Inc. Common Stock$4.03▼ 4.95%Market cap $307.59MP/E —$4.27$9.94
- IRDOpus Genetics Inc. Common Stock$3.84▼ 5.19%Market cap $307.14MP/E —$1.7$7.07
- LYELLyell Immunopharma Inc. Common Stock$8.12▼ 0.85%Market cap $348.21MP/E —$7.2$45
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| FHTX Foghorn Therapeutics Inc. Common Stock | $327.04M | — | $1.85 | ▼ 2.12% | $1.79$7.61 |
| GALT Galectin Therapeutics Inc. Common Stock | $324.74M | — | $3.62 | ▼ 2.43% | $2.03$7.13 |
| CATX Perspective Therapeutics Inc. Common Stock | $338.72M | — | $2.17 | ▼ 7.26% | $1.96$6.16 |
| ORGO Organogenesis Holdings Inc. Class A Common Stock | $310.11M | 84.95 | $1 | ▼ 9.91% | $1.13$7.08 |
| VNDA Vanda Pharmaceuticals Inc. Common Stock | $307.59M | — | $4.03 | ▼ 4.95% | $4.27$9.94 |
| IRD Opus Genetics Inc. Common Stock | $307.14M | — | $3.84 | ▼ 5.19% | $1.7$7.07 |
| LYEL Lyell Immunopharma Inc. Common Stock | $348.21M | — | $8.12 | ▼ 0.85% | $7.2$45 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Foghorn: Downgrade 'Sell' Eli Lilly Exit FHD-909 And Shift To Preclinical AssetsSeekingAlpha · 10/6/2026
- Friday's session: top gainers and losersChartMill · 10/2/2026
- FHTX Stock Extends Sell-Off After Lilly Collaboration Ends — Wedbush Slashes Target By 80%Yahoo · 10/2/2026
- These stocks are moving in today's sessionChartMill · 10/2/2026
- Wedbush Downgrades Foghorn Therapeutics to Neutral, Lowers Price Target to $2benzinga · 10/2/2026
- Friday's session: gap up and gap down stocksChartMill · 10/2/2026
- Foghorn Therapeutics layoffs after Eli Lilly ends cancer dealYahoo · 10/2/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 10/2/2026
- Correction: Top Midday DeclinersYahoo · 10/2/2026
Insider Activity
Insider Actions →- Neil Gallagher · June 24, 2026 · Grant28.0K @ $4.08
- Duty Stuart · June 24, 2026 · Grant28.0K @ $4.08
- Mendelsohn Michael · June 24, 2026 · Grant28.0K @ $4.08
- Biller Scott · June 24, 2026 · Grant28.0K @ $4.08
- Cole Douglas G. · June 24, 2026 · Grant28.0K @ $4.08
- Thomas J. Lynch Jr. · June 24, 2026 · Grant28.0K @ $4.08
- SMITH IAN F · June 24, 2026 · Grant28.0K @ $4.08
- GILL SIMBA · June 24, 2026 · Grant28.0K @ $4.08
- B. Lynne Parshall · June 24, 2026 · Grant28.0K @ $4.08
Institutional Ownership
March 31, 2026
- Total shares held
- 43.91M
- Total value held
- $209.55M
- Institutional holders
- 101
- Unknown12.67M
- Unknown6.05M
- Unknown5.84M
- Unknown4.39M
- Unknown2.60M
- Unknown2.36M
- Unknown1.57M
- Unknown1.50M
- Unknown848.2K
- Unknown720.7K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Foghorn and Lilly halt FHD-909 development
Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.
Foghorn and Lilly halt FHD-909 development. Foghorn Therapeutics announced it will not advance the FHD-909 program into the clinical development expansion phase with Lilly. This decision marks a significant setback for the company's pipeline, as it halts progress on a key partnership. The news explains why the stock is trading near its 52-week low, reflecting the impact of this strategic pause on market sentiment.